"ln fact, adult periodontitis and rheumatoid arthritis have much in common, so much so that I have argued that they are really the same disease." 1 he above bold and challenging statement may seem to be stretching the boundaries of conventional thought too far. However, close inspection of two of the most common chronic diseases afflicting humans reveals remarkable similarities that warrant further investigation.
The relationship between rheumatoid arthritis (RA) and the progression of inflammatory conditions elsewhere in the body, such as periodontitis, is controversial. While a number of studies have presented conflicting results regarding a relationship between periodontitis and RA, there have been recent reports suggesting a significant association between these two common chronic inflammatorv conditions. 2 6 In light of these reports, there is a need for further investigations to determine whether the severity of RA and the severity of periodontitis are interrelated. To do this, controlled, populationbased, laboratory, and clinical (molecular epidemiology) studies are needed to verify the immunological and biological associations between RA and periodontal disease.
PERIODONTAL DISEASES
The periodontal diseases range from the relatively benign form of gingivitis to aggressive periodontitis. Many of these conditions are not only a threat to the dentition, but may also be a threat to general health. There are reports suggesting increased prevalence of diabetes, atherosclerosis, myocardial infarction, and stroke in patients with periodontaldisease.T-e Thus, the likelihood of periodontal disease being associated with systemic diseases is becoming established fact. All forms of inflammatory periodontal disease are associated with chronic inflammation (accumulation of B and T lymphocytes as well as monocytes and neutrophils) , resulting in destruction of the periodontal ligament and bone' lf left untreated, significant tissue damage occurs, and the affected teeth can become loose and may be lost if the disease continues to be active. What is particularly curious about this disease is the great variability in presentation. Because of its multifactorial nature, which is modified by systemic, environmental, and microbiological factors, not all individuals are affected to the same degree despite the ubiquitous presence of dental plaque.
RHEUMATOID ARTHRITIS
Rheumatoid arthritis is also a chronic destructive inflammatory diseasel0 characterized by the accumulation and persistence of an inflammatory infiltrate in the synovial membrane that leads to synovitis and the destruction of the joint architecture resulting in impaired function. As a systemic disease, RA has extra-articular manifestations in systems such as the pulmonary, ocular, vascular, and other organs or structures that may be affected by the inflammatory process. The current paradigm for RA includes an initiating event (possibly a microbial exposure or a putative autoantigen) leading to significant synovial inflammation and tissue destruction. As for periodontitis, there is an accumulation of inflammatory cells (T and B lymphocytes, neutrophils, and monocytes), tissue edema, endothelial cell proliferation, and matrix degradation. RA is also modified by systemic, genetic, and environmental variables.
SIMILARITIES BETWEEN RHEUMATOID ARTHRITIS AND PERIODONTITIS Natural Historg
Periodontal disease. Natural history studies of periodontal disease in humans indicate the presence of three distinct subpopulations: 11 1) no progression of periodontal disease, in which around 10% of the population manifest vdry little or no disease which is of no particular consequence to the dentition; 2) moderate progression, affecting around B0% of the population and representing a very slowly progressing form of disease that generally can be easily managed via routine therapies; and 3) rapid progression, affecting approximately 8% of individuals whereby extensive periodontal destruction occurs which can be very difficult to control. Bartold, Marshall, From the natural history studies of RA and periodontitis, it has been observed that certain RA and periodontitis populations are characterized by a particular type of patient who will experience disease progression irrespective of any treatment provided. Whether the RA grouP, in which disease progression seems uncontrolled even after comprehensive treatment, is the same group that is susceptible to develop severe forms of periodontal disease remains to be established and is, indeed, a major thesis of this review.
Rheumatoid arthritis. At least three types of disease manifestation can also be observed in RA populations: 7) seltlimited: in these cases individuals originally presenting for RA have no evidence of disease 3 to 5 years later;12 2) eastlg controlled: Ihe disease is relatively easily controlled with only nonsteroidal anti-inflammatory drugs (NSAIDs);13 3) pro' gressiue: these patients generally require second-line drugs, which often still do not fully control the disease.14,l5
Etiologic Factors
Periodontitis. The periodontal diseases are well recognized as classic examples of chronic inflammatory diseases resulting from the induction of host inflammatory responses to the subgingival biofilm'
Gingivitis is typically characterized as a robust inflammatory response confined mainly to the superficial gingival connective tissues and is a relatively nonspecific response to a nonspecific accumulation of dental plaque. How gingivitis progresses to periodontitis is still unclear.l6
Periodontitis, on the other hand, appears to be a more specific inflammatory response to specific periodontal pathogens residing in the subgingival biofilm. Within the conditions known as periodontitis, there is considerable variability in terms of clinical manifestation and disease progression rates' This variability can be attributed to differences in composition of the subgingival microbial flora, as well as factors that modify the host response to the microbial challenge. Nonetheless, it must be noted that, although bacteria are necessary for disease initiation, they are not sufficient to cause disease progression unless there is an associated inflammatory response within a susceptible host.l6
Rheumatoid arthritis. Although the cause of RA is unknown, it has been recognized that many different arthritogenic stimuli activate infl ammatory resPonses in immunogenetically susceptible hosts. Thus, studies have focused on exogenous infectious agents, endogenous substances, such as connective tissue proteins (e.g., collagens and proteoglycans), and altered immunoglobulins as the causative candidates. The concept that RA is an infectious disease has been considered for over 70 years.r/ The idea that RA patients acquire an infection that elicits an immune response in the synovial membrane would account for some of the clinical features and would also explain the accumulation of immunocompetent T and B cells in the Iesions. Data from different animal models demonstrate that arthritis can develop secondarily to several different stimuli and through several different effector pathways. If such observations are also applicable to human RA, we might anticipate that different types of infections as well as other environmental exposures with capacity to induce excessive proinflammatory cytokines in genetically susceptible individuals may all potentially contribute to disease either in unison or isolation.
Are Bacteria a Common Etiologic Link Between Periodontitis and Rheumatoi"d A rthritis?
There are a number of shared features between microorganisms that can induce RA in a genetically susceptible host and the recognized periodontal pathogens. Nonetheless, RA is still not largely recognized as a disease resulting solely from bacterial challenge. On the other hand, technological and conceptual advances have permitted the identification of bacteria or groups of bacteria associated with specific periodontal diseases.ls Close inspection of the virulence factors of periodontal pathogens would suggest that such a response could be feasible. Thus, the possibility that ongoing periodontitis could trigger RA in genetically susceptible individuals is plausible.
Notwithstanding the above, these concepts remain speculative until the causative agent for RA can be definitively identified. To date, no infectious agents have been identified as the cause of RA in humans. Indeed, current information does not support the concept that a single antigen is responsible for synovial inflammation. It is possible that there is no single primary cause of RA and that different mechanisms may independently lead to synovial inflammation in susceptible individuals. It is important to recognize that, based on current information, we do not propose that periodontal pathogens cause, or are associated with, RA. The main focus of our attention is directed not towards causality but rather associations between two chronic inflammatory conditions that may have common underlying pathogenic mechanisms.
Immunogenetics
Periodontitis. [t has been reported that more than 50% of the variance in several features of chronic periodontitis can be explained by genetic fss1..r. l9'20 Many of these interindividual variables relate ro severity of periodontal destruction, and other inflammatory responses are attributed partly to the amount and type of cytokines that individuals produce.2l While the HLA-DR phenotype is not particularly strong for peri-odontitis, there is a report indicating that it is an important component of the genetic susceptibility to some forms of this disease. 22 In addition, polymorphisms in the interleukin-1 g (lL-1 B) gene cluster have been shown to have a significant correlation with some forms of periodontitis in certain populations. 23 Rheumatoid Arthritis. Family studies and studies on monozygotic and dizygotic twins have shown that RA has several features indicative of a complex genetic disease including genetic variance, incomplete penetrance, and multiple gene involvement. 24 For RA, the strongest genetic associations are found within the HLA genes.23 Using DNA sequencing and molecular-based typing, it has been demonstrated that the disease-conferring portion of the D region is confined to a short sequence within the third hypervariable region of HLA-DRB1 gene which includes the amino acid positions 67 through 74.2s'2o 11-,t" HLA genes and gender constitute about 30% ofthe genetic risk in RA, while other genetic factors such as cytokine genes, germline genes, and T-cell receptors also account for some of the genetic predisposition to RA.1o
Effector Mechanisms of Tissue Destruction in Rheumatoid Arthritis and Periodontitis
There is almost universal acceptance that a variety of cytokines and matrix metalloproteinases (MMPs) are upregulated and intimately involved in the pathogenesis of both periodontitis and RA; many of these effector molecules appear to be common to both diseases. The task now is to identify the specific cytokines, their concentrations, the cells they affect in vivo, the stages in which they are active, and the role and concentrations of their inhibitors. While the effects of cytokines on normal cellular process are important, it is their purported roles in pathophysiology that may result from excessive production, dysregulation, or inadequate inhibition that have gained most attention.l Very simply, cytokines can be classified into functional groups based on the cells of origin, and all major types have been identified and located in inflamed synovial and periodontal tissues.
Periodontitis has very similar cytokine profiles to p4,27'28 consisting of persistent high levels of proinflammatory cytokines, including lL-1B and tumor necrosis factor-alpha (TNF-ct), and low levels of cytokines which suppress the immunoinflammatory response such as IL-10 and transforming growth factor-B (TGF B). These cytokines, together with low levels of tissue inhibitors of metalloproteinases (TIMPs) and high levels of MMPs and prostaglandin E2 (PGE2), are associated with the active stages of periodontitis.
The destruction of soft and hard tissues seen in RA is also the result of not only a large number of cytokines d 5r d lr o p ri rl o a but also the sustained presence of other effector molecules released by resident and migrating cells. Together, these soluble mediators of inflammation are able to induce degradation of collagen and proteoglycans either through direct or indirect means. Productionof the arachidonic acid metabolite PGE2 as well as the release of neutrophil-associated enzymes, such as neutrophil elastase and B-glucuronidase, together with the secretion of matrix metalloproteinases by macrophages and synoviocytes, all contribute significantly to the pathogenesis of RA.
Formulation of the Hgpothesis On the basis of the above considerable similarities between the pathological and clinical features of RA and periodontitis (especially in the advanced and aggressive forms of these diseases), we have proposed that in some susceptible individuals, there are common features of an underlying and presently unknown dysregulation of the inflammatory mechanism which predisposes these individuals to advanced, aggressive, and severe forms of either disease.
Studies on Relationships Between Periodontitis and Rheumatoid Arthritis
To date, very few studies have examined the association between RA and periodontal disease, and the results have often been conflicting. For example, Finnish studies found no correlation between periodontal disease and arthritis,2e while others3,30 suggest a higher prevalence of periodontal bone loss in RA. A major reason for these discrepancies relates to the lack of uniformity in classifying the various forms of periodontal disease and RA. Indeed most of the early studies,3'29-31 failed to take into account the various forms of RA and periodontal disease and, as a result, grouped all subjects as either having RA or periodontal disease with little or no regard for subclassification for more detailed analyses. In light of these limitations, it is clear there is a need to re-examine the extent of the association between specific types of RA and periodontal disease. In particular, it is our thesis that the more aggressive or severe forms of periodontal disease and RA will show a very close correlation in terms of coexistence.
ln our first pilot study,6 investigating self-reported disease experience, the prevalence of moderate to severe periodontitis was significantly elevated in individuals with RA (uhadjusted relative risk of 4.7). In addition, the converse was also true in that periodontitis patients had a higher prevalence of RA compared to the general population (unadjusted relative risk of 1.5).
In a subsequent study, 65 patients attending a rheumatology clinic were studied for their level of periodontitis and RA.2 A control group consisted of ageand gender-matched individuals who did not have RA. No differences were noted for the plaque and bleeding indices between the control and RA groups. The RA group did, however, have significantly more missing teeth than the control group and a greater percentage of these subjects had deeper pocketing compared to the controls. The percentage of alveolar bone loss correlated positively with the principal parameters of RA severity.
These two pilot studies have resulted in several significant findings. Contrary to current dogma, RA patients do not have impaired oral hygiene (judged by plaque and bleeding scores). Perhaps more importantly, it was noted that individuals with severe RA are more likely to have advanced periodontitis and vice versa. Although many RA patients take medications that can reduce periodontal destruction (i.e., NSAIDs and immunosuppressants), we have noted significant periodontal destruction in these patients. This indicates that prior to the development of RA symptoms, the periodontitis was most likely developing and not detected. Thus, disease duration may be a very important factor. Finally, in order to understand the interrelationships between periodontitis and RA, it is necessary to categorize the disease on the basis of severity and duration (i.e., type of disease).
Recently, using an animal model, additional evidence has been presented to indicate a significant relationship between periodontitis and rheumatoid arthritis.32 From this study it was reported that inducing experimentalarthritis in the rat (adjuvant arthritis) resulted in periodontal breakdown characterized by alveolar bone loss and increased matrix metalloproteinase activity in adjacent gingival tissues. Interestingly, all of these reactions occurred without manipulating the oral or subgingival microflora.
Osteoclast Actioation and Vascular Damage -A Common Pathwag in Periodontitis and Rheumatoid Arthritis?
Most recently, studies from our laboratory (unpublished data) have begun to investigate the codistribution of cytokines involved in vascular damage and bone resorption in biopsies from graded rheumatoid arthritis and periodontitis lesions. Since the tumor necrosis factor (TNF)-like molecules and their receptors have been shown to be involved in both processes, we have chosen to study the receptor activator of nFkappa B ligand (RANKL), osteopretogerin (OPG), and TNF-related apoptosis inducing ligand (TRAIL) to determine at least one molecular mechanism common to both conditions. The cell surface TNF-like molecule, RANKL and its receptor, RANK have been shown to be key factors regulating osteoclast formation and activation.33'34 It has been shown that when RANKL binds to RANK on the surface of osteoclast precursors, these cells differentiate to form mature osteoclasts. It is now clear that RANKL, together with macrophage-colony stimulating factor (M-CSF), is required for osteoclast formation. The soluble TNF "receptor-like" molecule, OPG, is a natural inhibitor of RANKL.35 OPG btnds to RANKL and prevents its ligation to RANK. The importance of these molecules in regulating bone metabolism has been demonstrated by transgenic and gene knock-out studies in mice.36 Since these factors control physiologic osteoclast formation, it is reasonable to propose that they may also be key regulators of pathological bone resorption.3T'38 Although RANKL is normally provided by osteoblast-like cells in bone,38'3e there are reports suggesting that lymphocytes present in rheumatoid tissues may be the main source of RANKL in inflammatory arthritis.33'40 Furthermore, CD3+ T cells from the human rheumatoid joint express RANKL and can promote osteoclast formation from rodent spleen precursors.a0 In addition to lymphocyte production of RANKL, inhibition of RANKL by OPG treatment in vivo reduces both bone and cartilage destruction in a model of adjuvant arthritis.a I Under certain conditions, human osteoclasts are derived from osteoclast precursor cells present in or near to the tissues of arthritic joints.a2,a3 More recent reports in humans44,45 un4 animals4l show that RANK/RANKL interactions may be required for osteoclast formation and bone resorption in the RA joint. Accordingly, we have recently demonstrated that OPC and RANKL are expressed in biopsies of inflamed rheumatoid synovium and periodontitis lesions.46 In addition, we have found (unpublished data) that another ligand for OPG, TRAIL, is expressed in the both types of tissue (although not from the same patient). In these studies we have noted that OPC decreases with inflammation, RANKL increases with inflammation, and TRAIL increases with inflammation. These findings may be of considerable significance in light of OPG's ability to block the activity of TRAIL (and vice versa) and TRAIL's anti-inflammatory properties.aT
The production of OPG by endothelial cells may be significant for reasons other than its effects on bone metabolism, and there is now evidence to suggest that OPG might also regulate endothelial cell function. OPG has been reported to be required for endothelial cell survival and growth.as In addition, OPG knock-out mice have been shown to develop arterial calcifica-6on49,50 as well as severe osteoporosis, suggesting that vascular endothelial expression of OPC may have a role in vascular homeostasis.4l One of the most unexpected findings from our recent studies of diseased periodontal and synovial tissues was the observation that endothelial cells produce large amounts of OPG (unpublished observations). 2070 ln response to proinflammatory cytokines TNF-o and lL-1 P, OPG mRNA expression was dramatically enhanced, resulting in secretion of newly synthesized OPG and a reduction in cell-associated OPG. Such findings are consistent with our observations in vivo for active RA and periodontitis lesions. Vascular damage due to apoptosis is thought to precede vascular calcification5l and contribute to atherosclerosis. 52 In addition, diabetic endothelialcelldysfunction is associated with DNA damage induced by poly (ADPribose) polymerase activation. The exact cause of endothelial cell dysfunction is not known but it is possible that molecules such as TRAIL, expressed in nearby cells and tissues, may be important.38,53 9u, recent binding studies confirm that OPG binds to TRAIL, although with less affinity than RANKL, in vitro, and blocks its activity (unpublished data). The final piece of compelling evidence for the role of OPG in vascular damage comes from the fact that OPG knock-out mice develop vascular calcification. It is significant to note that calcification cannot be reversed by systemic treatment with recombinant OPG postpartum.5o This supports our concept that OPG must be expressed within the endothelial cells, either in an appropriate form or associated with other molecules, and this only occurs following normal synthesis within the healthy endothelial cells.
In light of the above, we propose that at least one underlying common molecular pathway in common between rheumatoid arthritis and periodontitis may lie within the RANK/OPG/TRAIL axis whereby OPG decreases leading to decreased vascular protection. In addition, with an increase in RANKL and TRAIL within the tissues, not only is vascular damage possible, but significant activation of osteoclasts may result. This proposal still awaits verification.
COMMON PATFIOGENESIS _ COMMON TREATMENT?
Current and Emerging Therapies Currently, the mainstream "first-line" modes of treatment for RA remain the NSAIDs such as aspirin, naproxen, diclofenac, and ibuprofen. Their mechanism of action through the inhibition of cyclooxygenase (COX) synthesis produces both analgesic and antipyretic properties. While these medications are effective in reducing the pain symptoms in RA, they do not significantly alter its course. 54 The use of NSAIDs for management of periodontal disease has been studied over the past 20 years.s5-57 While the results appear promising, the widespread clinical use of these medications to alter the course of periodontitis has not been universal. One particular problem with their use for the management of periodontitis appears to be a "rebound" effect to baseline following cessation of the medication.5s
With the discovery of two COX enzymes responsible for PGE2 production, designated COX-1 (constitutively expressed) and COX-2 (inducible), a variety of COX-2 inhibitors have been studied for their potential to stop or slow down bone resorption. One of the first COX-2 inhibitors developed, tenidap, has been shown to inhibit not only cyclooxygenase and PGE2 production but also IL-1, IL-6, and TNF-ct production. To date, COX-2 inhibitors have not been thoroughly studied for their potential to modify bone resorption in periodontitis.
In contrast to the NSAIDS, which do not significantly alter the course of RA, a newer family of medications designated disease-modifying anti-rheumatic drugs (DtvtARDs) has been developed. To be classified as a D/vlARD. the medication must demonstrate an ability to change the course of RA for at least 1 year as evidenced by sustained improvement in function, decreased synovitis, and prevention of further joint damage.5e Examples of these medications include parenteral gold salts, methotrexate, sulfasalazine, hydroxychloroquine (antimalarial drug), penicillamine, azathioprine, and leflunomide. A major drawback in the use of Dl4ARDs is their considerable toxicity.60 '61 The use of DMARDs for the management of periodontitis has been restricted largely due to the toxicity of elevated IL-1 in inflamed tissues.T2-74 Similarly, other studies have shown that blocking the activity of another important inflammatory cytokine, TNF-a, has therapeutic efficacy in RA patients.T5-78 The roles of IL-1 and TNF antagonists in a primate model of periodontitis have demonstrated a reduction in the inflammatory infiltrate in close proximity to bone as well as reduction in the formation of osteoclasts and reduced bone loss. 79 Clearly, many of these biologic agents, which target specific molecular events associated with acute and chronic inflammation, have significant potential to alter clinical outcomes for both RA and periodontal disease. With the emerging understanding that RA and periodontitis are multifactorial diseases, combination therapies that target multiple disease outcomes are also emerging. For example, in an animal study, it was reported that the administration of a combination of a chemically modifiedtetracycline (CMT-1) plus an NSAID, such as flurbiprofen or tenidap, synergistically inhibited severe bone destruction in arthritic rats, with the suppression of MMP activity in the joints.80'81 Similar encouraging results have been reported for periodontitis in humans. 82 Notwithstanding the above, it must be recognized that periodontitis differs in one significant way from RA through our understanding that the subgingival biofilm is a key etiologic factor. Unlike periodontal disease, no specific bacterial etiology has been identified for RA. Thus, while host modification of disease processes are possible for periodontitis, controlling the bacteria that cause periodontal infections remains a significant focus for periodontal treatment and prevention. At best, host modification can be only an adjunct treatment for periodontitis. However, until an etiologic factor can be found for RA, host modification remains the mainstay of treatment.
CONCLUSIONS
There is no question that periodontitis and RA have many pathologic features in common. Emerging evidence suggests a strong relationship between the extent and severity of periodontal disease and RA. While this relationship is unlikely to be causal, it is clear that individuals with advanced RA are more likely to experience more significant periodontal problems compared to their non-RA counterparts, and vice versa. Hence, the possibility exists that both conditions result from a common underlying dysregulation of the host inflammatory response. The precise nature of this dysregulation remains to be established.
There is accruing evidence to support the notion that both conditions manifest as a result of an imbalance between proinflammatory and anti-inflammatory cytokines. As a result, new treatment strategies will emerge for both diseases that may target the inhibition issues. However, the use of gold salts in an animal model has shown reduced periodontal destruction. 62 To date, no human studies have been performed.
Another emerging area of potential for host modulation in periodontitis and rheumatoid arthritis is control of the lvlMPs that are important mediators of ,tonnective tissue breakdown in both hard and soft tissues. In this regard, tetracyclines and various chemianalogues have been found to inhibit MMP activity a mechanism that is independent of their antimiproperty.63,64 A number of clinical trials using dose tetracycline to modify periodontitis have carried out, with the most recent data indicating low-dose doxycycline is safe and significantly ef-65'66 5on"11'teless, it is still recommended that data be interpreted with caution to differentiate statistically signifi cant and clinically relevant 67 The role of MMP inhibitors in managing RA been less well studied but promising results are ing.68-zo In particular, a recent study has demthat low-dose and antimicrobial (higher) doxycycline, when used adjunctively with meth-, produces enhanced improvements in global of RA severitv in humans than methotrexate with placebo.Tl
Control of cytokines and their receptors is also as a field of considerable promise. For ex-, blocking the lL-1 receptor and using gene to deliver IL-1 receptor antagonist are two under investigation to modulate the effect of proinflammatory cytokines and destructive pro_ teases. Through a better understanding of these rwo com_ mon chronic inflammatory conditions, it is hoped that areas of similarity can be exploited to determine the true relationship between these diseases and com_ mon areas of treatment. Already, it can be predicted that the periodontal status of paiients with RA should be carefully screened.
